spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  vemurafenib 

 HSMN NewsFeed - 30 Jun 2021
Mitsubishi Tanabe Pharma America Announces EXSERVAN(TM) (riluzole) is Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2018
Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI(R) (binimetinib)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 23 Mar 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 20 Feb 2018
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2015
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Biopharmaceuticals Oncology Dermatology
 HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jul 2014
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2013
Plexxikon Announces Program Update and Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2012
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2012
Plexxikon Announces European Approval of Zelboraf(R) for the Treatment of Patients With BRAF Mutation-Positive Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Aug 2011
FDA Approves Zelboraf (Vemurafenib) and Companion Diagnostic for BRAF Mutation-Positive Metastatic Melanoma, a Deadly Form of Skin Cancer
Biopharmaceuticals Oncology Personalized Medicine FDA
 HSMN NewsFeed - 4 Apr 2011
Daiichi Sankyo Completes Plexxikon Acquisition
Biopharmaceuticals Mergers & Acquisitions
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.